Kriya Announces Thirteen Presentations at the American Society of …
Apr 29, 2025 · Kriya is a biopharmaceutical company developing gene therapies to address chronic diseases affecting millions of people around the world. With operations in Research Triangle Park, …
Metabolic Disease: Gene Therapy for Diabetes and NASH - Kriya …
Kriya is developing KRIYA 839, a potential one-time gene therapy for type 1 diabetes expressing insulin and glucokinase, designed to be delivered intramuscularly with the objective of driving durable …
Kriya Announces $320 Million Series D Financing to Advance Pipeline …
Sep 10, 2025 · Kriya’s pipeline includes focally delivered gene therapies for chronic diseases, including Geographic Atrophy, Thyroid Eye Disease, Type 1 Diabetes, Metabolic Associated Steatohepatitis …
Newsroom: Gene Therapy Pipeline News - Kriya Therapeutics
Sep 12, 2024 · Kriya shares the latest news on our pipeline of life-changing gene therapies to address common diseases.
Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene ...
Sep 12, 2024 · KRIYA-586 is an investigational adeno-associated virus (AAV) gene therapy product engineered to express an antibody that inhibits Insulin-Like Growth Factor 1 Receptor (IGF1R), a key …
Site Map - Kriya Therapeutics
About Us Science What We Do News Careers Kriya Therapeutics ® Research Triangle Park – North Carolina Silicon Valley – California Contact 1-833-Kriya-TX (1-833-574-9289) info@kriyatx.com
Kriya Announces $150 Million Addition to its Series C, Bringing Total ...
Jul 26, 2023 · With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $600 million in committed capital, which will be used to advance a broad pipeline of …
Kriya Appoints Sachiyo Minegishi as Chief Financial Officer
Jan 5, 2026 · Ms. Minegishi will oversee execution of Kriya’s corporate strategy, scaling of financial operations and planning for commercialization as the company advances multiple gene therapies …
Kriya Announces Gene Therapy Program for Thyroid Eye Disease
Jan 5, 2024 · Kriya is developing KRIYA-586, a one-time, adeno-associated virus (AAV) gene therapy that drives durable expression of a monoclonal antibody that blocks IGF-1 receptors.
Opthalmology: Gene Therapy for Geographic Atrophy - Kriya …
Kriya is developing KRIYA-825, a potential one-time gene therapy for Geographic Atrophy that expresses a fusion protein designed to inhibit the activity of complement C3 and C5, with the …